ERBB2 and breast carcinoma: Notably, in the BT-474 cell line, expression of the three receptors ER+, PR+, and HER2+ is detected, hereby bridging the gap between the luminal and non-luminal breast cancer subtypes, and as such, constituting a relevant model for both in vivo and in vitro studies [5].